Slide 1: Cyclopharm Limited: A profitable and growing market leader
For personal use only Cyclopharm Limited A profitable and growing market leader in nuclear medical imaging and lung healthcare Bioshares Biotech Summit 2016 29 July 2016 1
Slide 2: CYC's 10 Fast Facts
CYC’s 10 Fast Facts For personal use only 1. Technegas is a well established proprietary world leader in functional lung ventilation imaging technology with multiple revenue streams consisting of: service income, capital equipment and 84% of sales generated from single patient consumables 2. Techneg
Slide 3: Our Technology
Our Technology For personal use only Manufacturer and • Invented in 1986 distributor of pulmonary • Track record of growing revenue, ventilation imaging devices profits and cash flows and equipment • USFDA Phase 3 trials for sales in US progressing • Functional lung ventilation imaging agent histori
Slide 4: Our Strategy
Our Strategy For personal use only CYC has clear strategy to leverage our position as a leading player in the global nuclear medicine imaging market and lung health space to expand the use of our proprietary products and introduce new innovative technology. We will do this by: 1. Attaining approval
Slide 5: The Growth Challenge
For personal use only The Growth Challenge Summit Session Lead Questions: 1. How does a company leverage its existing asset base to achieve a step change in growth once a core business has been established? 2. What are the considerations that need to be made with respect to changes in risk profile f
Slide 6: Our History
Our History For personal use only 1984 1992 2000 2001 2007 2013 Technegas European markets Vita Life Sciences USFDA Technegas Plus UltraluteTM discovered and established acquires program initiated generator launched technology commercialised Tetley Medical for Technegas established 1985 1995 2000 20
Slide 7: How is Cyclopharm leveraging its existing asset base to achieve a step change in growth
For personal use only 1. How is Cyclopharm leveraging its existing asset base to achieve a step change in growth once a core business has been established? • Leveraging the success of our proven Technegas technology o Maximising opportunities in existing markets o Expansion into new markets o Expans
Slide 8: Considerations on risk profile, cash burn and delayed profitability
For personal use only 2. What are the considerations that need to be made with respect to changes in risk profile for the company, a higher cash burn and lower or delayed profitability for the overall business? Survival In the struggle of survival, the fittest win out at Maintained focus on our co
Slide 9: Considerations for a company's shareholder base when positioning for growth
For personal use only 3. What are the considerations for a company's shareholder base if changes are made to position a company for growth? In General: • Delivering shareholder value is dependent on optimising the link between business strategy and capital management o i.e. generate a return on asse
Slide 10: Shareholder base considerations (Continued)
For personal use only 3. What are the considerations for a company's shareholder base if changes are made to position a company for growth? (Continued) In Cyclopharm’s experience: • We have enjoyed the stable and consistent support of a funding group of shareholders who share the company's vision •
Slide 11: Our Growth Plan Deliverables
Our Growth Plan Deliverables For personal use only Where we are Today: • Technegas sold in 55 countries delivering ~200,000 patient studies primarily in the diagnosis of Pulmonary Embolism • We expect to continue low single digit growth in our existing markets with a few notable underdeveloped excep
Slide 12: Disclaimer
For personal use only Disclaimer Corporate Head Office Certain views expressed here contain information derived from publicly available sources that have not Cyclopharm Limited been independently verified. Building 75 Business & Technology Park New Illawarra Road The presentation include certain sta